Evidence map›Paper›PMID 31067275›Full record

ArticlePloS one2019

The chromatin structuring protein HMGA2 influences human subtelomere stability and cancer chemosensitivity.

Syed Moiz Ahmed, Priya Dharshana Ramani, Stephen Qi Rong Wong, Xiaodan Zhao, Roland Ivanyi-Nagy, Tang Choong Leong, Clarinda Chua, Zhizhong Li, Hannes Hentze, Iain BeeHuat Tan and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Syed Moiz AhmedSchool of Biological Sciences, Nanyang Technological University, Singapore.
Priya Dharshana RamaniSchool of Biological Sciences, Nanyang Technological University, Singapore.
Stephen Qi Rong WongBiological Resource Centre, Agency for Science, Technology and Research (A*STAR), Singapore.
Xiaodan ZhaoMechanobiology Institute, National University of Singapore, Singapore.
Roland Ivanyi-NagySchool of Biological Sciences, Nanyang Technological University, Singapore.
Tang Choong LeongDepartment of Colorectal Surgery, Singapore General Hospital, Singapore.
Clarinda ChuaGenome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore.
Zhizhong LiGenomics Institute of the Novartis Research Foundation, San Diego, California, United States of America.
Hannes HentzeBiological Resource Centre, Agency for Science, Technology and Research (A*STAR), Singapore.
Iain BeeHuat TanGenome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore.
Jie YanMechanobiology Institute, National University of Singapore, Singapore.
Ramanuj DasGuptaGenome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore.
Peter DrögeSchool of Biological Sciences, Nanyang Technological University, Singapore.ORCID 0000-0001-5447-738X
Agency for Science, Technology and Research · SGNanyang Technological University · SGNational University of Singapore · SGGenomics Institute of the Novartis Research Foundation · USSingapore General Hospital · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The transient build-up of DNA supercoiling during the translocation of replication forks threatens genome stability and is controlled by DNA topoisomerases (TOPs). This crucial process has been exploited with TOP poisons for cancer chemotherapy. However, pinpointing cellular determinants of the best clinical response to TOP poisons still remains enigmatic. Here, we present an integrated approach and demonstrate that endogenous and exogenous expression of the oncofetal high-mobility group AT-hook 2 (HMGA2) protein exhibited broad protection against the formation of hydroxyurea-induced DNA breaks in various cancer cells, thus corroborating our previously proposed model in which HMGA2 functions as a replication fork chaperone that forms a protective DNA scaffold at or close to stalled replication forks. We now further demonstrate that high levels of HMGA2 also protected cancer cells against DNA breaks triggered by the clinically important TOP1 poison irinotecan. This protection is most likely due to the recently identified DNA supercoil constraining function of HMGA2 in combination with exclusion of TOP1 from binding to supercoiled substrate DNA. In contrast, low to moderate HMGA2 protein levels surprisingly potentiated the formation of irinotecan-induced genotoxic covalent TOP1-DNA cleavage complexes. Our data from cell-based and several in vitro assays indicate that, mechanistically, this potentiating role involves enhanced drug-target interactions mediated by HMGA2 in ternary complexes with supercoiled DNA. Subtelomeric regions were found to be extraordinarily vulnerable to these genotoxic challenges induced by TOP1 poisoning, pointing at strong DNA topological barriers located at human telomeres. These findings were corroborated by an increased irinotecan sensitivity of patient-derived xenografts of colorectal cancers exhibiting low to moderate HMGA2 levels. Collectively, we uncovered a therapeutically important control mechanism of transient changes in chromosomal DNA topology that ultimately leads to enhanced human subtelomere stability.

Indexed as

Cell Line, TumorChromatinDNA Breaks, Double-StrandedDNA ReplicationDNA Topoisomerases, Type IFemaleGene Expression Regulation, NeoplasticHMGA2 ProteinHumansMaleTelomereChromatinDNA Topoisomerases, Type IHMGA2 ProteinTOP1 protein, human

Identifiers

PMID31067275
PMCPMC6505889
OpenAlexW2949067578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.